# Validation data for Anti-CoV2RBD-bam-mIgG2a & Anti-CoV2RBD-ete-mIgG2a

https://www.invivogen.com/sars2-spike-lycov-mab

For research use only

Version 21J22-EG

Anti-CoV2RBD-ete-mIgG2a and Anti-CoV2RBD-bam-mIgG2a are recombinant monoclonal antibodies (mAbs) featuring the variable region of the LY-CoV016 (aka Etesevimab) and LY-CoV555 (aka Bamlavinimab) human mAbs, respectively. They both feature a mouse IgG2a constant region and they specifically target the SARS-CoV-2 Spike receptor-binding domain (RBD). The binding of these antibodies has been validated by ELISA, using coated SARS-CoV-2 Spike-RBD proteins derived from the Wuhan **(Figure 1A)**, United Kingdom **(Figure 1B)**, and South-Africa **(Figure 1C)** variants, as well as an Anti-mIgG2a-HRP secondary antibody. CR3022-derived Anti-Spike-RBD-mIgG2a and Anti-βGal mIgG2a have been used as controls.

## Binding of Anti-CoV2RBD-ete-mIgG2a and Anti-CoV2RBD-bam-mIgG2a to RBD variants




**Figure 1:** SARS-CoV-2 Spike-RBD proteins (3 µg/ml) derived from the Wuhan **(A)**, United Kingdom (U.K.) **(B)**, or South-Africa (S.A.) **(C)** variants were coated on ELISA plates overnight. A 3-fold serial dilution of Anti-CoV2RBD-bam-IgG2a (red curve), Anti-CoV2RBD-ete-mIgG2a (orange curve), CR3022-derived Anti-Spike-RBD mIgG2a (back curve), of Anti-βGal-mIgG2a antibodies (grey curve) was performed for the capture step. A HRP-labelled Anti-mIgG2a antibody (1/1000 dilution) and the HRP substrate OPD (o-phenylenediamine dihydrochloride) were used for the detection step. Absorbance was read at 490 nm.


TECHNICAL SUPPORT
InvivoGen USA (Toll-Free): 888-457-5873
InvivoGen USA (International): +1 (858) 457-5873
InvivoGen Europe: +33 (0) 5-62-71-69-39
InvivoGen Asia: +852 3-622-34-80
E-mail: info@invivogen.com